Late Stage Chronic Kidney Disease Drugs Market Worth US$ 11,096.9 Million by 2027

According to our new market research study titled" Late Stage Chronic Kidney Disease Drugs Market - Global Analysis and Forecast by Product Type, Indication and Distribution Channel" the global late stage chronic kidney disease drugs market is expected to reach US$ 11,096.9 million by 2027 from US$ 4,680.0 million in 2019; it is estimated to grow at a CAGR of 11.6% from 2020 to 2027. The report highlights the trends prevalent in the global late stage chronic kidney disease drugs market, and the drivers and deterrents pertaining to its growth.

Download Sample PDF at https://www.theinsightpartners.com/sample/TIPRE00013768/?utm_source=OpenPR&utm_medium=10379

AbbVie Inc.; Amgen; AstraZeneca; Sanofi; Kyowa Kirin Co., Ltd.; Takeda Pharmaceutical Company Limited; Astellas Pharma Inc.; Bayer AG; Vifor Pharma Management Ltd.; and Akebia Drugs, Inc. are among the prominent players operating in the late stage chronic kidney disease drugs market. The market players are focused on organic strategies to sustain their position in the market. For instance, in Jul-2020, Bayer announced positive results from the Phase III FIDELIO-DKD study, assessing the efficacy and safety of finerenone versus placebo when added to standard of care for chronic kidney disease (CKD) in patients with type 2 diabetes (T2D), has met its primary endpoint.

Chronic kidney disease (CKD) is a common and life-threatening condition that affects 1 in 10 people worldwide. It affects more than 26 million Americans and millions more worldwide. High blood pressure and diabetes were the two major causes in 75% of kidney failure cases between 2015 and 2017. 47% of new end-stage kidney disease (ESKD) patients had a primary diagnosis of diabetes, while 29% of new end-stage kidney disease patients had a primary diagnosis of hypertension. Moreover, according to Bayer's press release, about 29 million people in the US have type 2 diabetes, and 40% will develop CKD in the coming year.

Speak to Analyst @ https://www.theinsightpartners.com/speak-to-analyst/TIPRE00013768?utm_source=OpenPR&utm_medium=10379

According to the CDC, 1 in 3 adults with diabetes and 1 in 5 adults with high blood pressure might have chronic kidney disease. In 2015, 30.3 million people in the US had diabetes as per the American Diabetes Association (ADA). According to the CDC, in 2014, around 118,000 people in the US have started the treatment for end-stage renal disease, and the number of people for treatment is expected to increase as more people become aware of this condition. Moreover, the CDC states that around 96% of the people with kidney damage are not aware of having chronic kidney disease, which indicates the underlying market prospective in the late stage of chronic kidney disease drugs. These factors are expected to enhance market growth during the forecast period.

The market growth is also attributed to a few key factors such as high prevalence of diseases leading to chronic kidney diseases and favorable reimbursement policy for the late stage chronic kidney disease drugs. However, delay in the diagnosis of chronic kidney disease is expected to hamper the growth of the market up to certain extent during the forecast period.

Get a Full Report Copy @ https://www.theinsightpartners.com/buy/TIPRE00013768/?utm_source=OpenPR&utm_medium=10379

The Report Segments the Global Late Stage Chronic Kidney Disease Drugs Market as Follows:

By Product Type
Calcimimetics
Vitamin D
Sterols
Potassium Binders
Calcium-Based Phosphate Binders

By Indication
Late Stage Chronic Kidney Disease Induced Hyperparathyroidism
Late Stage Chronic Kidney Disease Induced Hyperphosphatemia
Late Stage Chronic Kidney Disease Induced Hyperkalaemia

By Distribution Channel
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies

Contact US
Contact Person : Ankit Mathur
Phone : +1-646-491-9876
E-mail : sales@theinsightpartners.com

About US
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, FAM20B Gene, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Food and Beverages, Consumers and Goods, Chemicals and Materials.

This release was published on openPR.